We are live on ! Find out more
AI

Allostery Investments Portfolio holdings

AUM $7.85M
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$69.3M
AUM Growth
-$26.4M
Cap. Flow
-$17.7M
Cap. Flow %
-25.58%
Top 10 Hldgs %
65.25%
Holding
56
New
16
Increased
11
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$4.49M
2
ABVX
Abivax
ABVX
+$3.44M
3
BBIO icon
BridgeBio Pharma
BBIO
+$2.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$2.68M
5
PCVX icon
Vaxcyte
PCVX
+$2.56M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$982K
2
DFTX
Definium Therapeutics
DFTX
+$905K
3
DNTH icon
Dianthus Therapeutics
DNTH
+$545K
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$496K
5
JSPR icon
Jasper Therapeutics
JSPR
+$470K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
26
Pliant Therapeutics
PLRX
$64.4M
$596K 0.86%
+441,686
New +$2.68M
CNTX icon
27
Context Therapeutics
CNTX
$42.2M
$582K 0.84%
950,166
– –
PHGE icon
28
BiomX
PHGE
$1.76M
$523K 0.75%
49,507
+15,621
+46% +$218K
RLYB icon
29
Rallybio
RLYB
$87.6M
$492K 0.71%
94,029
-6,396
-6% -$40.4K
ELDN icon
30
Eledon Pharmaceuticals
ELDN
$297M
$339K 0.49%
100,000
– –
CLYM
31
Climb Bio
CLYM
$772M
$299K 0.43%
244,988
– –
ORKA
32
Oruka Therapeutics
ORKA
$6.06B
$205K 0.3%
20,000
– –
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$11.7B
$199K 0.29%
+600
New +$197K
ETNB
34
DELISTED
89bio
ETNB
$182K 0.26%
+25,000
New +$219K
PMN icon
35
ProMIS Neurosciences
PMN
$131M
$165K 0.24%
9,348
+1,544
+20% +$32.8K
LEGN icon
36
Legend Biotech
LEGN
$3.97B
$161K 0.23%
+4,750
New +$170K
VIR icon
37
Vir Biotechnology
VIR
$1.5B
$144K 0.21%
+22,202
New +$197K
WVE icon
38
Wave Life Sciences
WVE
$1.2B
$141K 0.2%
+17,500
New +$191K
ARQT icon
39
Arcutis Biotherapeutics
ARQT
$3.18B
$117K 0.17%
+7,500
New +$106K
EWTX icon
40
Edgewise Therapeutics
EWTX
$4.65B
$66K 0.1%
+3,000
New +$78.7K
LXEO icon
41
Lexeo Therapeutics
LXEO
$367M
$17.5K 0.03%
5,054
– –
ANAB icon
42
CALL
AnaptysBio
ANAB
$1.67B
– –
-50,000
Closed -$662K
APLS
43
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-80,000
Closed -$2.55M
CRNX icon
44
Crinetics Pharmaceuticals
CRNX
$8.93B
– –
-9,700
Closed -$496K
DNTH icon
45
Dianthus Therapeutics
DNTH
$6.09B
– –
-25,000
Closed -$545K
ELEV
46
DELISTED
Elevation Oncology
ELEV
– –
-432,206
Closed -$243K
JSPR icon
47
Jasper Therapeutics
JSPR
$25.1M
– –
-22,000
Closed -$470K
DFTX
48
Definium Therapeutics
DFTX
$6.02B
– –
-130,000
Closed -$905K
NVAX icon
49
PUT
Novavax
NVAX
$1.28B
– –
-150,000
Closed -$1.21M
OLMA icon
50
CALL
Olema Pharmaceuticals
OLMA
$1.04B
– –
-90,000
Closed -$525K
1
2
3

Similar funds

CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Allostery Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Allostery Investments held 56 positions worth $69.3M, down 28% from $95.7M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Allostery Investments withdrew a net $17.7M in Q1 2025, closing 15 positions and reducing 5 holdings. Its most notable exit was Definium Therapeutics, an estimated $905K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 53% a quarter earlier.

Against the trend, Allostery Investments opened a new position in BridgeBio Pharma worth $2.77M.

  • Allostery Investments's largest Q1 2025 buy was BridgeBio Pharma: 80,000 shares worth $2.77M.
  • Allostery Investments added most to Merus in Q1 2025, an estimated $4.49M increase.
  • Allostery Investments's biggest Q1 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $982K.
  • Allostery Investments fully exited Definium Therapeutics in Q1 2025, selling an estimated $905K.
  • Allostery Investments's ten largest holdings make up 65% of its $69.3M portfolio in Q1 2025.
  • Allostery Investments opened 16 new positions and closed 15 in Q1 2025.
  • Allostery Investments's portfolio value fell 28% quarter-over-quarter to $69.3M.

Based on Allostery Investments's 13F filing for Q1 2025, filed 15 May 2025.